Ultragenyx Pharmaceutical Inc.
RARE
Market Cap$3.69B
Close$
$55.30
53.7% upside
Current Fair Value
53.7% upsideUndervalued by 53.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.69 Billion |
|---|---|
| Enterprise Value | $3.56 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-6.29 |
| Beta | 0.61 |
| Outstanding Shares | 95,681,451 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -6.61 |
|---|---|
| PEG | 40.36 |
| Price to Sales | 7.2 |
| Price to Book Ratio | 17.99 |
| Enterprise Value to Revenue | 6.8 |
| Enterprise Value to EBIT | -6.66 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Ultragenyx Pharmaceutical Inc.
CEO: Emil Kakkis